Skip to main content
Log in

Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

It is still uncertain whether total bilirubin per se is a risk factor for osteoporosis in postmenopausal women and no study has so far examined this important issue. This study was designed to assess the sheer effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. In the present study, postmenopausal female subjects without potential liver disease (n = 918) who underwent measurement of bone mineral density were enrolled. Correlation and logistic regression analysis were used to assess the relationship between total bilirubin and other variables. As a result, subjects with osteoporosis had a significantly lower total bilirubin level (P = 0.005). A 0.1 mg/dl increase in total bilirubin was associated with reduced odds ratio of the risk by 38 % for osteoporosis [OR 0.62 (95 % CI 0.52–0.88), P = 0.012] after adjustment for several variables. Total bilirubin was independently associated with BMD [coefficient = 0.41, 95 % CI (0.35–0.47), P < 0.001 for lumbar spine and coefficient = 0.44, 95 % CI (0.36–0.48), P < 0.001 for femur neck]. A positive correlation could be observed with significant difference between total bilirubin and z-score (r = 0.33, P < 0.001 for lumbar spine and r = 0.37, P < 0.001 for femur neck) and total bilirubin was positively correlated with serum calcium (r = 0.13, P < 0.001) as well. Therefore, this study demonstrates an independent inverse association between total bilirubin and the prevalence of osteoporosis in postmenopausal women without potential liver disease. Total bilirubin would be useful as a provisional new risk factor of osteoporosis in such a population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hay JE (1995) Bone disease in cholestatic liver disease. Gastroenterology 108:276–283

    Article  PubMed  CAS  Google Scholar 

  2. Leslie WD, Bernstein CD, Leboff MS (2003) AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125:941–966

    Article  PubMed  Google Scholar 

  3. Conn HO (1981) A peek at the Child-Turcotte classification. Hepatology 1:673–676

    Article  PubMed  CAS  Google Scholar 

  4. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PCJ (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864–871

    Article  PubMed  CAS  Google Scholar 

  5. Pares A, Rodes J (2003) Natural history of primary biliary cirrhosis. Clin Liver Dis 7:779–794

    Article  PubMed  Google Scholar 

  6. Roll J, Boyer JL, Barry D, GB Klatskin (1983) The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 308:1–7

    Article  PubMed  CAS  Google Scholar 

  7. Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE (1999) Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29:39–43

    Article  PubMed  CAS  Google Scholar 

  8. Menon KVN, Angulo P, Weston S, Dickson ER, Lindor KD (2001) Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 35:316–323

    Article  PubMed  CAS  Google Scholar 

  9. Ormarsdóttir S, Ljunggren O, Mallmin H, Michaëlsson K, Lööf L (2002) Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol 14:43–48

    Article  PubMed  Google Scholar 

  10. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER (1995) Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 21:389–392

    PubMed  CAS  Google Scholar 

  11. Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, Dubreuil M, Peris P, Enjuanes A, Martinez de Osaba MJ, Alvarez L, Monegal A, Combalia A, Parés A (2011) Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 54:2104–2113

    Article  PubMed  Google Scholar 

  12. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report no. 843. World Health Organization, Geneva

  13. Kanis JA, Melton LJ 3rd, Christiansen C, Johnson CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141

    Article  PubMed  CAS  Google Scholar 

  14. van ‘t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F (1998) Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 97:2302–2306

    Article  PubMed  Google Scholar 

  15. Newton J, Francis R, Prince M, James O, Bassendine M, Rawlings D, Jones D (2001) Osteoporosis in primary biliary cirrhosis revisited. Gut 49:282–287

    Article  PubMed  CAS  Google Scholar 

  16. Kuyumcu ME, Yesil Y, Oztürk ZA, Cınar E, Kızılarslanoglu C, Halil M, Ulger Z, Yesil NK, Cankurtaran M, Arıoğul S (2012) The association between homocysteine (hcy) and serum natural antioxidants in elderly bone mineral densitometry (BMD). Arch Gerontol Geriatr 55:739–743

    Article  PubMed  CAS  Google Scholar 

  17. Halliwell B (1994) Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344:721–724

    Article  PubMed  CAS  Google Scholar 

  18. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A (2003) Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88:1523–1527

    Article  PubMed  CAS  Google Scholar 

  19. Zhang YB, Zhong ZM, Hou G, Jiang H, Chen JT (2011) Involvement of oxidative stress in age-related bone loss. J Surg Res 169:e37–e42

    Article  PubMed  CAS  Google Scholar 

  20. Sánchez-Rodríguez MA, Ruiz-Ramos M, Correa-Muñoz E, Mendoza-Núñez VM (2007) Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord 8:124

    Article  PubMed  Google Scholar 

  21. Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J (2002) Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine betasynthase-deficient mice. Arterioscler Thromb Vasc Biol 22:34–41

    Article  PubMed  CAS  Google Scholar 

  22. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM, Luo SQ (2004) Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 314:197–207

    Article  PubMed  CAS  Google Scholar 

  23. Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Partington GA, Urry ZL, Chambers TJ (2003) A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 112:915–923

    PubMed  CAS  Google Scholar 

  24. Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ (2005) Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146:728–735

    Article  PubMed  CAS  Google Scholar 

  25. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046

    Article  PubMed  CAS  Google Scholar 

  26. Stocker R, Glazer AN, Ames BN (1987) Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA 84:5918–5922

    Article  PubMed  CAS  Google Scholar 

  27. Stocker R, Peterhans E (1989) Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid. Free Radic Res Commun 6:57–66

    Article  PubMed  CAS  Google Scholar 

  28. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD (1996) Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 51:859–862

    Article  PubMed  CAS  Google Scholar 

  29. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D (1998) Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys 352:165–174

    Article  PubMed  CAS  Google Scholar 

  30. Baranano DE, Rao M, Ferris CD, Snyder SH (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99:16093–16098

    Article  PubMed  CAS  Google Scholar 

  31. Lin JP, Vitek L, Schwertner HA (2010) Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 56:1535–1543

    Article  PubMed  CAS  Google Scholar 

  32. Kirkby KA, Adin CA (2006) Products of heme oxygenase and their potential therapeutic applications. Am J Physiol Renal Physiol 290:F563–F571

    Article  PubMed  CAS  Google Scholar 

  33. Sabio JM, Vargas-Hitos JA, Mediavilla JD, Navarrete-Navarrete N, Zamora-Posadas M, Pérez-Vicente S, Hidalgo-Tenorio C, Díaz-Chamorro A, Jáimez L, Jiménez-Alonso J, Grupo Lupus Virgen de las Nieves (2010) Correlation of asymptomatic hyperuricaemia and serum uric acid levels with arterial stiffness in women with systemic lupus erythematosus without clinically evident atherosclerotic cardiovascular disease. Lupus 19:591–598

    Article  PubMed  CAS  Google Scholar 

  34. Zhang Z, Bian L, Choi Y (2012) Serum uric acid: a marker of metabolic syndrome and subclinical atherosclerosis in Korean men. Angiology 63:420–428

    Article  PubMed  Google Scholar 

  35. Makovey J, Macara M, Chen JS, Hayward CS, March L, Seibel MJ, Sambrook PN (2013) Serum uric acid plays a protective role for bone loss in peri-and postmenopausal women: a longitudinal study. Bone 52:400–406

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank all the numerous physicians and study nurses who participated in data collection.

Conflict of interest

All other authors have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yoon-Ho Choi.

Additional information

L.-Q. Bian, R.-Z. Li and Z.-Y. Zhang contributed equally to this work.

About this article

Cite this article

Bian, LQ., Li, RZ., Zhang, ZY. et al. Effects of total bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. J Bone Miner Metab 31, 637–643 (2013). https://doi.org/10.1007/s00774-013-0452-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-013-0452-y

Keywords

Navigation